Qorvo, a Greensboro, NC-based provider of innovative radio frequency (RF) solutions, has been awarded a $24.4 million contract with the National Institutes of Health (NIH) through the Rapid Acceleration of Diagnostics (RADx) initiative. The contract, awarded to Qorvo Biotechnologies, a wholly owned subsidiary of Qorvo, helps advance the production and market launch of the Qorvo Omnia diagnostic test platform.
Qorvo Biotechnologies’ covid-19 antigen test was recently granted emergency use authorization (EUA) by the FDA. The Qorvo Omnia platform represents a paradigm shift in diagnostic testing capability by using high frequency Bulk Acoustic Wave (BAW) sensors to achieve rapid SARS-CoV-2 (covid-19) antigen testing. BAW sensor technology enables low limit of detection (LOD) levels that are similar to molecular testing capability.
Read Qorvo Gets FDA EUA for Omnia Rapid Covid-19 Antigen Testing
NIH launched RADx in the early months of the pandemic to speed innovation in the development and commercialization of technologies for covid-19 testing. “Qorvo’s RF-based diagnostic technology has met review criteria to become a part of the RADx portfolio,” says Tiffani Bailey Lash, PhD, co-program lead for the RADxTech program. “Qorvo’s antigen test has a lot of potential with near-PCR-level accuracy for use at point-of-care settings.”
James Klein, president of Qorvo Biotechnologies, says, “Widespread testing with rapid and reliable results plays a critical role in helping public health officials respond to infectious disease outbreaks. We are committed to supporting the ongoing fight against covid-19 as well as expanding the availability of tools with broader applicability.”
Qorvo has more than 30 years of experience working with government contracts and has shipped billions of products containing its BAW RF technology across a range of industries.
For more information, visit Qorvo Biotechnologies.
